Azenta Reports Fourth Quarter and Full Year Fiscal 2024 Results; Announces the Plan to Sell B Medical Systems and Appoints Lawrence Y. Lin as CFO

FY'24 revenue growth of 4%, reported and organic, in combined Sample Management Solutions and Multiomics FY'25 organic revenue growth expected to be 3% to 5% year over year, with Adjusted EBITDA margin expansion of approximately 300 basis points Pursuing a sale of B Medical Systems to simplify portfolio and drive revenue growth and profitability Announces appointment of Lawrence Y. Lin as Chief Financial Officer; Herman Cueto to remain as advisor to ensure smooth transitionBURLINGTON, Mass., Nov. 12, 2024 ...